— Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses — — Data Presented During Late-Breaking Science Session at European Society of Cardiology (ESC) Congress 2022 in Barcelona — DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 26, 2022 (GLOBE NEWSWIRE) — Amarin […]
Other News
Imbria Presents Positive Clinical Data for Ninerafaxstat from IMPROVE-DiCE at the European Society of Cardiology Congress 2022
Treatment with ninerafaxstat significantly improved cardiac energetics, steatosis and left ventricular (LV) diastolic function in patients with type-2 diabetes mellitus (T2DM) and obesity BOSTON, Mass., Aug. 26, 2022 (GLOBE NEWSWIRE) — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced positive […]
Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway
ANN ARBOR, Mich., Aug. 26, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that bempedoic acid (NEXLETOL®) is now recommended as an important oral non-statin therapy for LDL-cholesterol (LDL-C) lowering in the management of atherosclerotic cardiovascular disease (ASCVD) by the American College of Cardiology (ACC) task force on expert […]
Aziyo Biologics Appoints Michelle LeRoux Williams, Ph.D as Chief Scientific Officer
Renown Pioneer in Regenerative Medicine to Lead Company’s Pipeline Development Initiatives SILVER SPRING, Md., Aug. 26, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company announced today that Michelle LeRoux Williams, Ph.D. has been appointed Chief Scientific Officer. “Aziyo strives to have the best products […]
The Polypill Reduces Cardiovascular Mortality by 33% in Patients Treated After Myocardial Infarction
MADRID–(BUSINESS WIRE)–The polypill developed by the CNIC and Ferrer, which includes three drugs (aspirin, an angiotensin-converting enzyme (ACE) inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack. The polypill reduces mortality from cardiovascular causes in this population by 33%. This is […]
89bio Presents Positive Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at European Society of Cardiology Congress 2022
-Results featured in a late-breaking oral presentation- -Treatment with pegozafermin demonstrated consistent and significant benefit in triglyceride (TG) reduction as well as improvements in liver fat and glycemic control- -Positive data support the advancement into a Phase 3 trial in SHTG- SAN FRANCISCO, Aug. 26, 2022 (GLOBE NEWSWIRE) — 89bio, […]
Investor Insights: Sabir Rassiwalla – How Has MedTech’s Changing Landscape Brought You to CRG? (Part 1)
McDermott + Bull Partner Ken Dropiewski talks with CRG Director Sabir Rassiwalla about what drove him to CRG after a long tenure with Abbott.
LATEST DATA DEMONSTRATES PENUMBRA SYSTEM AND RED® REPERFUSION CATHETERS EFFECTIVE FOR BROAD STROKE CARE
Initial INSIGHT Registry data demonstrated RED® reperfusion catheters were highly effective in removing all clot types with an impressive 68.9% mTICI > 2b-3 overall first pass effect rate COMPLETE study sub-analyses of tandem lesions and late window showed aspiration thrombectomy with Penumbra System® restored blood flow and resulted in improved 90-day […]
Alexandra Clyde appointed to Sequana Medical Board of Directors
Seasoned medtech leader with more than 30 years’ healthcare experience Ghent, Belgium – 25 August 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company. Ms. Clyde is a highly experienced global business executive […]
Fewer hospitalizations for home-based cardiac rehab patients
Kaiser Permanente study showed patients in home-based cardiac rehabilitation had fewer hospitalizations than those in center-based cardiac rehabilitation PASADENA, Calif., Aug. 25, 2022 /PRNewswire/ — Patients who participated in in-home cardiac rehabilitation had fewer hospitalizations over 12 months than patients who participated in center-based cardiac rehabilitation, according to a Kaiser Permanente study published August […]



